Discovering Optimal Weight Loss Interventions To Prevent Osteoarthritis In Obesity Through The Lens Of Early Biomarkers: The TANGO Diet Trial
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Osteoarthritis (OA) is the most common type of arthritis, and an obese population increases the disease burden of OA. Weight-loss is the first line management for symptom relief but is unclear whether weight loss can prevent OA changes in the joint. Biological OA markers can pick up early disease changes long before any signs on routine X-ray. My research will look at the effect of weight loss by very low energy diet on early OA biomarker in patients with overweight or obesity.
Testosterone Intervention For The Prevention Of Diabetes Mellitus In High Risk Men: A Randomised Trial
Funder
National Health and Medical Research Council
Funding Amount
$5,054,654.00
Summary
Type 2 diabetes (T2DM) is increasingly common, costly and deadly. Some men at risk of T2DM have low testosterone (T) levels. Our preliminary data suggests that T treatment may prevent the development of T2DM, and improve cardiovascular and sexual function, body composition and bone density, and mood. This remains to be fully tested in a randomized placebo-controlled trial, and this project will do so in a 2-year study of T treatment compared to placebo in men at risk of T2DM participating in a l ....Type 2 diabetes (T2DM) is increasingly common, costly and deadly. Some men at risk of T2DM have low testosterone (T) levels. Our preliminary data suggests that T treatment may prevent the development of T2DM, and improve cardiovascular and sexual function, body composition and bone density, and mood. This remains to be fully tested in a randomized placebo-controlled trial, and this project will do so in a 2-year study of T treatment compared to placebo in men at risk of T2DM participating in a lifestyle program.Read moreRead less
The Treatment Of BOoking Gestational Diabetes Mellitus Study: The TOBOGM Study
Funder
National Health and Medical Research Council
Funding Amount
$2,197,280.00
Summary
Gestational diabetes mellitus (GDM) related pregnancy complications are reduced with treatment from 24-28 weeks pregnant. Many women are diagnosed/treated earlier without evidence of benefit and possible risk of harm. In TOBOGM women under 20 weeks pregnant with mildly raised blood glucose will be allocated by chance to either immediate treatment, or awaiting a repeat diabetes test at 24-28 weeks pregnant to decide treatment. Harmful and beneficial effects on mother and baby will be compared.
Fenofibrate And Microvascular Events In Type 1 Diabetes (FAME 1) Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,883,529.00
Summary
Diabetes is one of the commonest cause of blindness in adults. Vision loss, which is irreversible, is a most feared complication of diabetes. A blood fat lowering drug called fenofibrate, available in Australia, has been shown to reduce eye damage in people with Type 2 diabetes by 35-40%, and to prevent eye damage in Type 1 diabetic animal models. This study will evaluate the potential benefits of fenofibrate in 450 adults with Type 1 diabetes who have early diabetic eye damage.
Obesity and insulin resistance are an escalating health problem in Australian adolescents. Unmanaged, they are likely to progress to type 2 diabetes and early atherosclerosis and which may pose a major burden on health care resources. However, treatment strategies are currently limited because of the lack of evidence. This PhD research aims to identify, summarise and test an effective and evidence-based approach of dietary management for overweight/obese adolescents and older children with clini ....Obesity and insulin resistance are an escalating health problem in Australian adolescents. Unmanaged, they are likely to progress to type 2 diabetes and early atherosclerosis and which may pose a major burden on health care resources. However, treatment strategies are currently limited because of the lack of evidence. This PhD research aims to identify, summarise and test an effective and evidence-based approach of dietary management for overweight/obese adolescents and older children with clinical insulin resistance or prediabetes.Read moreRead less
Free-Living Closed-Loop Insulin Delivery For Patients With Type 1 Diabetes: A Long-term Multi-centre Randomized Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,041,986.00
Summary
Closed loop technology for automating the delivery of insulin to patients with Type 1 diabetes has the potential to improve the lives of many with the disease. Though early prototypes are currently under evaluation in small studies, no studies have yet to date applied the technology in a large scale randomised trial. We propose to undertake such a study in order to demonstrate the utility of this technology and facilitate its eventual routine and widespread use in the community in the future.
Bisphosphonate Therapy With Zoledronate Or Tenofovir Switching To Improve Low Bone Mineral Density In HIV-Infected Adults: A Strategic, Randomised Trial
Funder
National Health and Medical Research Council
Funding Amount
$716,300.00
Summary
Most HIV+ Australians receive tenofovir, a ‘preferred’ drug in all HIV treatment guidelines, and may do for decades, as HIV therapy is lifelong and because there are very few new HIV drugs. 40% of HIV+ adults have low bone density and HIV+ adults experience more fractures. Of all HIV drugs, tenofovir causes the most bone loss. This trial compares two approaches: a drug to improve bone density and switching tenofovir to another drug. This ‘treat versus switch’ approach is a world-first for HIV.
Cystic Fibrosis - Insulin Deficiency, Early Action (CF-IDEA)
Funder
National Health and Medical Research Council
Funding Amount
$185,485.00
Summary
Cystic Fibrosis (CF) is the most common life-threatening genetic condition affecting Australian children. As well as repeated lung infections, children with CF develop insulin deficiency and eventually diabetes. The CF-IDEA trial (Cystic Fibrosis – Insulin Deficiency, Early Action) will determine whether starting insulin treatment before the onset of diabetes (earlier than current practice) will improve the health of children with CF by improving body weight and lung function.